Identification and Validation of a m5C RNA Modification-Related Gene Signature for Predicting Prognosis and Immunotherapeutic Efficiency of Gastric Cancer

Figure 6

Treatment analysis of the high- and low-risk groups. (a) ESTIMATE difference scores for the high- and low-risk groups, based on the ESTIMATE comprehensive score and the matrix score. (b) Differences analysis in tumor purity between the high- and low-risk groups, having a significantly lower tumor purity of the high-risk group. (c) Immune cells proportion in the high- and low-risk groups, targeting tumor-infiltrating immune cells in each sample. (d) The lollipop chart depicting the correlation analysis of the risk value and immune cells.

(a)

(b)

(c)

(d)